Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland; Institute of Pathology Ente Ospedaliero Cantonale (EOC), Locarno, Switzerland.
Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Mod Pathol. 2024 Apr;37(4):100440. doi: 10.1016/j.modpat.2024.100440. Epub 2024 Jan 28.
Primary bone lymphoma (PBL) is rare and mostly represented by diffuse large B-cell lymphomas (DLBCL). Follicular lymphoma (FL), albeit commonly disseminating to the bone marrow, rarely presents primarily as bone lesions. Here, we studied 16 patients (12 men:4 women, median age 60 years) who presented with bone pain and/or skeletal radiologic abnormalities revealing bone FL. Lesions were multifocal in 11 patients (spine ± appendicular skeleton), and unifocal in 5 patients (femoral, tibial, or vertebral). An infiltrate of centrocytes and centroblasts (CD20+ CD5- CD10+ BCL2+ BCL6+) with abundant reactive T cells and an increased reticulin fibrosis massively replaced the marrow spaces between preserved bone trabeculae. The pattern was diffuse ± nodular, often with paratrabecular reinforcement and/or peripheral paratrabecular extension. Ki-67 was usually <15%. Two cases had necrosis. BCL2 rearrangement was demonstrated in 14 of 14 evaluable cases (with concomitant BCL6 rearrangement in one). High-throughput sequencing revealed BCL2, KMT2D, and TNFRSF14 to be the most frequently mutated genes. After staging, 5 qualified for PBL (3 limited stage) and 11 had stage IV systemic FL. All patients received rituximab ± polychemotherapy as firstline treatment, and 7 received local therapy (6 radiotherapy and 2 surgery). Three patients experienced transformation to DLBCL. At the last follow-up (15/16, median 48 months), 11 patients achieved complete remission, including all cases with PBL and most patients with limited extraosseous disease (3-year progression-free survival 71%). One patient died of unrelated cause (3-year overall survival 91%). FL may manifest as a localized or polyostotic bone disease. A minority represent PBL, whereas most reveal systemic disease.
原发性骨淋巴瘤(PBL)较为罕见,主要表现为弥漫性大 B 细胞淋巴瘤(DLBCL)。滤泡淋巴瘤(FL)虽然通常播散至骨髓,但很少以单纯的骨病变为首发表现。在此,我们研究了 16 名患者(男 12 例,女 4 例,中位年龄 60 岁),他们表现为骨痛和/或骨骼影像学异常,提示存在骨 FL。11 例患者的病变为多灶性(脊柱+四肢骨骼),5 例患者为单灶性(股骨、胫骨或椎体)。大量反应性 T 细胞浸润的中心细胞和中心母细胞(CD20+ CD5- CD10+ BCL2+ BCL6+)弥漫性或结节状替代保留骨小梁之间的骨髓腔。模式为弥漫性±结节性,常伴有小梁旁强化和/或小梁旁外周延伸。Ki-67 通常<15%。2 例有坏死。14 例可评估病例中有 14 例显示 BCL2 重排(1 例同时伴有 BCL6 重排)。高通量测序显示 BCL2、KMT2D 和 TNFRSF14 是最常突变的基因。分期后,5 例符合 PBL(3 例局限期),11 例为 IV 期全身性 FL。所有患者均接受利妥昔单抗±化疗作为一线治疗,7 例接受局部治疗(6 例放疗,2 例手术)。3 例患者发生转化为 DLBCL。末次随访(16 例中的 15 例,中位随访时间 48 个月)时,11 例患者达到完全缓解,包括所有 PBL 患者和大多数局限性骨外疾病患者(3 年无进展生存率 71%)。1 例患者死于无关原因(3 年总生存率 91%)。FL 可表现为局限性或多灶性骨病。少数代表 PBL,而大多数则表现为全身性疾病。